What does Voxtur Bio Limited do?

Voxtur Bio Limited manufactures in-vitro diagnostic (IVD) kits, reagents, and medical consumables for clinical laboratories. IVD products are used for diagnostic testing of blood, urine, and other body samples outside the living body, supporting disease diagnosis and monitoring across hospitals and diagnostic centers.

When was Voxtur Bio Limited incorporated?

The company was incorporated in 2012 in Maharashtra and is registered with the Registrar of Companies in Mumbai (CIN: U25190MH2012PLC238544), with its headquarters in Thane, Maharashtra.

What regulatory approvals does Voxtur Bio require?

As an IVD manufacturer, Voxtur Bio is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Medical Devices Rules, 2017. Products must obtain requisite licenses and approvals before commercialization, and the company's manufacturing facility must comply with Good Manufacturing Practices (GMP) standards.

Who are the competitors of Voxtur Bio?

In the domestic IVD market, Voxtur Bio competes with established Indian manufacturers including Transasia Bio-Medicals, Agappe Diagnostics, Tulip Diagnostics, and Meril Life Sciences. On the international side, it faces competition from multinational IVD giants like Roche Diagnostics, Abbott, Siemens Healthineers, and bioMerieux.

How do I buy Voxtur Bio unlisted shares here?

Raise an enquiry on any company with the quantity you want. Our desk sources the shares and comes back with a firm price and allocation. You accept the allocation, transfer the funds to the desk's published bank account, and once we verify payment the shares are transferred into your demat.

Who am I actually transacting with?

You transact with the desk, not with an anonymous counterparty. When you buy, you buy from the desk; when you sell, you sell to the desk. Shares always route through the desk's own demat account, so there's one accountable party for the whole trade.

How do I pay, and is there a payment gateway?

Payment is by direct bank transfer to Prospire Network Private Limited's published account (CIN U82300UP2025PTC233622), shown to you in-app at the payment step. There is no card gateway and no escrow. Never pay to a personal account or to any account shared over phone, WhatsApp or email — even if the person claims to be from our team.

How long does settlement take?

After you accept an allocation, you have a short window to pay (typically 2 days). Once payment is verified, shares are usually credited to your demat within 2–3 business days, subject to depository timelines and any company-level restrictions. Timeframes are typical, not guaranteed.

There are no separate platform fee lines and no GST on the transfer — the desk's margin is built into the buy/sell price you're quoted. The only statutory add-on on a purchase is stamp duty on the consideration, shown transparently in your cost breakdown.

Is there a minimum ticket size for Voxtur Bio?

Minimums vary by company and depend on the lot the desk can source. Raise an enquiry and the desk will confirm the available quantity and the minimum for that name.

What KYC do I need, and do I need a demat account?

You'll share your demat details when you enquire so we can settle directly. Full KYC — PAN and a client-master / demat statement — is required before the transfer step, when shares actually change hands. Yes, you need an active demat account to hold unlisted shares.

Are there lock-ins on unlisted or pre-IPO shares?

Some shares carry statutory or company-imposed lock-ins — for example, a post-listing lock-in on pre-IPO stock — and transfers can be subject to the company's articles or approvals. Where a lock-in applies, we'll flag it before you commit.

How do I sell Voxtur Bio shares I already hold?

Raise a sell enquiry with the company, quantity and your target price. The desk confirms a buying price, you transfer your shares into the desk's demat, and once the credit is verified we pay you out by bank transfer to your registered account. The desk never pays out before your shares are received.

Unlisted shares are illiquid, may be hard or impossible to sell, and are not covered by exchange settlement guarantees or investor-protection funds. Pricing is indicative, not live. Read the full Risk Disclosure before you enquire, and invest only what you can afford to lock away.

Voxtur Bio Unlisted Share Price | Buy Voxtur Bio Pre-IPO Shares — wisefolio

Investment Thesis

Voxtur Bio Limited is a promising but small-scale IVD diagnostics manufacturer based in Vasai, Maharashtra, known for its VoxPress rapid test kits and VoxEl ELISA kits for infectious diseases. With ₹51.4 Cr revenue in FY2024 and a 38% growth trajectory, the company is scaling organically in a high-demand segment backed by government health programmes. Key challenges include its tiny team size, absence of recent institutional funding, and competition from large multinational diagnostics companies.

Pros

Strong revenue growth: ₹51.4 Cr in FY24 with 38% 1-year revenue CAGR and 51% EBITDA CAGR — among the fastest growing IVD companies in India
Full regulatory compliance: FDA licensed, GMP certified, ISO 9001:2015 and ISO 13485:2016 accredited manufacturing
Diversified IVD product portfolio covering HIV, HCV, toxoplasma, rubella, herpes, CMV, dengue — addresses critical public health diagnostics
Backed by institutional investors (White Whale Ventures, Equity Intelligence) and 45+ angel investors with $3.16M raised
Operates in high-demand, policy-backed diagnostics market (National Health Mission, Ayushman Bharat procurement)

Cons

Very small company (~₹51 Cr revenue) with only 15 employees — scale and execution capacity are significant limitations
MCA industry classification as "Rubber Products" manufacturer is incongruent with actual IVD diagnostics business — possible regulatory/classification ambiguity
Latest funding was in November 2019 — no recent funding rounds suggest possible investor-growth gap
Competes against large established IVD players (Abbott, SD Biosensor, Agappe, Span Diagnostics) with much larger distribution and R&D budgets

Business Segments

Rapid Diagnostic Test Kits (Point-of-Care) — VoxPress product line (HIV, HCV, dengue, malaria etc.)

ELISA Test Kits — VoxEl product line (toxoplasma, rubella, herpes, CMV)

Blood Collection Tubes (Vactube brand)

Laboratory Plastic Consumables

Febrile Antigen Reagents and Latex Testing Kits

Blood Grouping Sera

Revenue Model

Voxtur Bio generates revenue by selling IVD kits, diagnostic reagents, and medical consumables to hospitals, diagnostic chains, clinical laboratories, and government healthcare institutions. Revenue likely flows from both direct institutional sales and distribution partnerships.

Detailed Analysis

Growth outlookExpansion plans, industry tailwinds & headwinds8

Growth Plans

India's IVD market estimated to grow from ~$1.5 billion to $3+ billion by 2027, providing substantial headroom for domestic manufacturers

Government's Production Linked Incentive (PLI) scheme for medical devices supports domestic manufacturing scale-up

Post-COVID expansion of diagnostic testing infrastructure in Tier 2 and Tier 3 cities

Industry Tailwinds

Recent Developments

FY2024 revenue of ₹51.4 Cr with EBITDA CAGR of 51% — strongest financial performance on record

Employee count reached 15 as of September 2024, growing 16% YoY — lean but expanding team

No new funding rounds announced between 2020 and 2025; company appears to be scaling organically

Comparable Companies

CompanyTypeTickerMkt Cap

Transasia Bio-MedicalsUnlisted——

Agappe DiagnosticsUnlisted——

Meril Life SciencesUnlisted——

Transasia Bio-MedicalsUnlisted

Agappe Diagnostics

Frequently Asked Questions

About Voxtur Bio

Voxtur Bio Limited is a Thane-based in vitro diagnostics (IVD) company incorporated on December 6, 2012, under CIN U25190MH2012PLC238544. The company develops, manufactures, and markets diagnostic kits and reagents for clinical laboratories, hospitals, and point-of-care testing settings. Registered at Plot No. A-1, Royal Compound, Village Kaman, Bhiwandi Road, Thane, Maharashtra, Voxtur Bio operates in the precision diagnostics space. The company's primary product lines are VoxPress and VoxEl — point-of-care and clinical immunoassays respectively. VoxPress is designed for rapid point-of-care diagnostic tests, while VoxEl covers clinical laboratory immunoassays. These products address infectious disease testing, including HIV, Hepatitis C (HCV), toxoplasma, rubella, herpes simplex virus, and Cytomegalovirus (CMV). Voxtur Bio also manufactures consumables and related reagents for the broader clinical diagnostics market. For FY2024, Voxtur Bio reported revenues of Rs. 51.4 crore, reflecting a 1-year revenue CAGR of 38% and an EBITDA CAGR of 51%. The company has raised $3.16 million (approximately Rs. 26 crore) over three funding rounds from 49 investors, indicating broad early-stage investor participation. As of September 2024, the company had approximately 15 employees, reflecting a lean, high-efficiency operating model. The IVD sector in India is growing rapidly driven by India's expanding private hospital network, increasing diagnostic testing volumes post-COVID, and government schemes such as Ayushman Bharat expanding access to diagnostics. Voxtur Bio's focus on infectious disease testing aligns with India's significant disease burden in infectious diseases, creating strong tailwinds for its core product lines. With authorised share capital of Rs. 6.5 crore and paid-up capital of Rs. 6.37 crore, Voxtur Bio is a small but rapidly growing IVD company positioning itself in the high-margin diagnostic reagents and consumables segment.

Key Milestones

Incorporated on 6 December 2012 in Maharashtra as a Public Limited company

Common questions about unlisted shares

How do I buy Voxtur Bio unlisted shares here?
Raise an enquiry on any company with the quantity you want. Our desk sources the shares and comes back with a firm price and allocation. You accept the allocation, transfer the funds to the desk's published bank account, and once we verify payment the shares are transferred into your demat.
Who am I actually transacting with?
You transact with the desk, not with an anonymous counterparty. When you buy, you buy from the desk; when you sell, you sell to the desk. Shares always route through the desk's own demat account, so there's one accountable party for the whole trade.
How do I pay, and is there a payment gateway?
Payment is by direct bank transfer to Prospire Network Private Limited's published account (CIN U82300UP2025PTC233622), shown to you in-app at the payment step. There is no card gateway and no escrow. Never pay to a personal account or to any account shared over phone, WhatsApp or email — even if the person claims to be from our team.

Voxtur Bio Limited

How settlement works

Get price alerts for Voxtur Bio Limited

Discuss Voxtur Bio

Similar companies

Other ways to invest